These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29855987)

  • 1. Finasteride use during pregnancy and early neonatal outcome: a case report.
    AlSaad D; Lee BH; Al-Obaidly S
    Int J Clin Pharm; 2018 Aug; 40(4):803-805. PubMed ID: 29855987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta).
    Prahalada S; Tarantal AF; Harris GS; Ellsworth KP; Clarke AP; Skiles GL; MacKenzie KI; Kruk LF; Ablin DS; Cukierski MA; Peter CP; vanZwieten MJ; Hendrickx AG
    Teratology; 1997 Feb; 55(2):119-31. PubMed ID: 9143092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride-induced secondary infertility associated with sperm DNA damage.
    Tu HY; Zini A
    Fertil Steril; 2011 May; 95(6):2125.e13-4. PubMed ID: 21292254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
    Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
    J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
    Prescrire Int; 2016 Oct; 25(175):242. PubMed ID: 30688421
    [No Abstract]   [Full Text] [Related]  

  • 7. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W; Leerunyakul K; Suchonwanit P
    Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss.
    Won YY; Lew BL; Sim WY
    Dermatol Ther; 2018 Mar; 31(2):e12588. PubMed ID: 29464847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ; Dhurat RS
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary infertility due to use of low-dose finasteride.
    Şalvarci A; Istanbulluoğlu O
    Int Urol Nephrol; 2013 Feb; 45(1):83-5. PubMed ID: 23070721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
    Boyapati A; Sinclair R
    Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat.
    Bowman CJ; Barlow NJ; Turner KJ; Wallace DG; Foster PM
    Toxicol Sci; 2003 Aug; 74(2):393-406. PubMed ID: 12773767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
    Gupta MA; Vujcic B; Gupta AK
    Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraindicated use of 5-alpha-reductase inhibitors in women.
    Teichert M; van Puijenbroek E; Stricker BH
    Br J Clin Pharmacol; 2017 Feb; 83(2):429-431. PubMed ID: 27567019
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.